XOMA Corp Files 8-K/A Amendment
Ticker: XOMAP · Form: 8-K/A · Filed: Jun 13, 2024 · CIK: 791908
| Field | Detail |
|---|---|
| Company | Xoma Corp (XOMAP) |
| Form Type | 8-K/A |
| Filed Date | Jun 13, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0075, $0.05, $0.0001, $2.5879 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
TL;DR
XOMA Corp filed an amendment to its 8-K, cleaning up financial docs from April 3rd.
AI Summary
XOMA Corporation filed an amendment (8-K/A) on June 13, 2024, to its report originally filed on April 3, 2024. This amendment primarily concerns financial statements and exhibits related to the company's reporting period ending April 3, 2024. The filing does not appear to introduce new material events but rather amends or clarifies previously submitted information.
Why It Matters
This filing indicates XOMA Corporation is making corrections or additions to previously filed financial information, which could be important for investors assessing the company's financial health.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing, likely for clarification or correction of financial statements and exhibits, rather than a report of a new material event.
Key Players & Entities
- XOMA Corporation (company) — Registrant
- 0000791908 (company) — Central Index Key
- April 3, 2024 (date) — Earliest Event Reported Date
- June 13, 2024 (date) — Filing Date
FAQ
What is the purpose of this 8-K/A filing?
This filing is an amendment (Amendment No. 1) to a previously filed Form 8-K, primarily to update or correct financial statements and exhibits.
What was the original report date for the event being amended?
The earliest event reported date for the original filing was April 3, 2024.
When was this amendment filed with the SEC?
This amendment was filed as of date June 13, 2024.
What is XOMA Corporation's industry classification?
XOMA Corporation's Standard Industrial Classification is Pharmaceutical Preparations [2834].
Where is XOMA Corporation headquartered?
XOMA Corporation is located at 2200 Powell Street, Suite 310, Emeryville, California.
Filing Stats: 987 words · 4 min read · ~3 pages · Grade level 10.8 · Accepted 2024-06-13 16:31:36
Key Financial Figures
- $0.0075 — nge on which registered Common Stock, $0.0075 par value XOMA The Nasdaq Global Ma
- $0.05 — ve Perpetual Preferred Stock, par value $0.05 per share XOMAP The Nasdaq Global M
- $0.0001 — nding shares of common stock, par value $0.0001 per share, of Kinnate Biopharma Inc., a
- $2.5879 — f February 16, 2024 in exchange for (i) $2.5879 in cash per share, plus (ii) one non-tr
Filing Documents
- d814270d8ka.htm (8-K/A) — 38KB
- d814270dex231.htm (EX-23.1) — 4KB
- d814270dex992.htm (EX-99.2) — 83KB
- d814270dex995.htm (EX-99.5) — 161KB
- g814270g36p63.jpg (GRAPHIC) — 3KB
- g814270g74o58.jpg (GRAPHIC) — 3KB
- 0001193125-24-160743.txt ( ) — 488KB
- xoma-20240403.xsd (EX-101.SCH) — 4KB
- xoma-20240403_def.xml (EX-101.DEF) — 14KB
- xoma-20240403_lab.xml (EX-101.LAB) — 24KB
- xoma-20240403_pre.xml (EX-101.PRE) — 15KB
- d814270d8ka_htm.xml (XML) — 8KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (a)
Financial Statements of Businesses Acquired
Financial Statements of Businesses Acquired The financial statements of Kinnate as of and for the three months ended March 31, 2024 (unaudited), as of and for the three months ended March 31, 2023 (unaudited) and as of and for the years ended December 31, 2023 and 2022 (audited) are filed as Exhibit 99.2, Exhibit 99.3 and Exhibit 99.4, respectively, to this Amendment and incorporated herein by reference. (b) Pro Forma Financial Information The unaudited pro forma condensed combined balance sheet as of March 31, 2024, the unaudited pro forma condensed combined statement of operations for the three months ended March 31, 2024, the unaudited pro forma combined statement of operations for the year ended December 31, 2023, and notes to the unaudited pro forma condensed combined financial information of the Company, all giving effect to the acquisition, are filed as Exhibit 99.5 to this Amendment and incorporated herein by reference. (d) Exhibits Exhibit No. Description 2.1+ Agreement and Plan of Merger between XOMA, Kinnate and Purchaser, dated February 16, 2024 (incorporated herein by reference to Exhibit 2.1 to Form 8-K filed by XOMA Corporation on February 16, 2024). 2.2+ Contingent Value Rights Agreement, dated April 3, 2024, by and between XOMA Corporation, XRA 1 Corp., Broadridge Corporate Issuer Solutions, LLC and Fortis Advisors LLC (incorporated herein by reference to Exhibit 2.2 to Form 8-K filed by XOMA Corporation on April 3, 2024). 23.1 Consent of KPMG LLP, Independent Registered Public Accounting Firm. 99.1+ Press Release issued by XOMA Corporation on April 3, 2024 (incorporated herein by reference to Exhibit (a)(5)(D) to the Schedule TO-T/A filed by XOMA Corporation on April 3, 2024). 99.2 Unaudited Condensed Consolidated Financial Statements of Kinnate Biopharma Inc. as of and for the three Months Ended March 31, 2024 99.3 Unaudited Condensed Consolidated Financial Statements of Kinnate Biopharma Inc. as of and for the
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XOMA CORPORATION Date: June 13, 2024 By: /s/ Owen Hughes Name: Owen Hughes Title: Chief Executive Officer